Cite
HARVARD Citation
Wei, Y. et al. (2021). Low‐dose decitabine plus venetoclax is safe and effective as post‐transplant maintenance therapy for high‐risk acute myeloid leukemia and myelodysplastic syndrome. Cancer science. 112 (9), pp. 3636-3644. [Online].